Atherogenesis has been linked to low concentrationsof high-densitylipoproteinand its principalcarrier protein,apolipoprotein (apo) A-I,in serum. We measured apo A-I by enzyme-linked immunosorbent assay, using polyclonal antiserum raised against purified apo A-I and conjugated to peroxidase. During storage at 4#{176}C and above, the immunoreactivity of apo A-I increased so that measured values in stored serum were difficult to interpret. The immunoreactivity of serum apo A-I also increased substantially (up to 50-fold) during exposure to Nal04. This increase was apo A-I concentrationdependent,was linearlydependentonthe concentration of Na104 up to 200 mmol/L at pH 7.4 and 25#{176}C, and was not ascribable to nonspecific binding of antibody-peroxidase conjugateto the reactionwells. Treatment with Na104 caused apo A-I immunoreactivity to increase to a peak or plateau, then gradually decline. In 100 mmol/L NaIO4 (pH 7.4, 25#{176}C), this plateau occurred30-60 mm after oxidation commenced. When frozen serum and stored nonfrozen serum were both oxidized with Na104 under the same conditions, the apo A-I from the frozen serum had a significantly (P = 0.0004) greater increase in immunoreactivity.
I
We have been exploring the feasibility of screening forl ape A-I and ape B in blood samples spotted onto filterl paper, as routinely collected from all neonates in developedi countries two to five days postpartum, and in serum sam-I plea from adults (12, 13). However, in measuring ape A-I,I we and others have encountered changes in immunoreac-I tivity of the apolipeprotein with time and temperature oil storage (at 4#{176}C and room temperature), both in the serum and the blood-spot samples (12, 14-16). Different methodsl have given different results, but most investigators havel found an increase in ape A-I immunoreactivity during storage at 4#{176}C or at room temperature, as measured by both enzyme-linked immunosorbent assay (EUSA) and radioimmunoassay (RIA) methods (14) (15) (16) . This has occurred whether polyclonal or some monoclonal antibodies were used in the assays. Despite several investigations, the mechanisms have not been identified. In the present study we examined the effects of delipidation, denaturation, reduction, and oxidation of serum on ape A-I immunoreactivity as measured by an ELISA assay. We found that the oxidation of serum ape A-I had the greatest effect on increasing its immunoreactivity.
Materials and Methods

ELISA determination
of apo A-I in serum. We measured the concentrations of ape A-I in serum by a previously reported sandwich ELISA method (12), in which both capture and labeled antibodies were sheep pelyclonal anti-ape A-I antiserum (lot no. 10243020-05; Boehringer Mannheim, Mannheim, F.R.G.). The antiserum was raised by immunizing sheep with purified ape A-I protein preparations (M. Kiene, Boehringer Mannheim GmbH, personal communication).
The labeled antibody was covalently at tached to horseradish peroxidase (EC 1.11.1.7) as described elsewhere (17) . We used flat-bottom, quality-certified, 96-well microtiter plates (lot no. 4087, Nunc-Immuno Plate I; Nunc, Roskilde, Denmark). The color reaction used, oxidation of o-phenylenediamine with hydrogen peroxide, was monitored at 490 nm with a Dynatech MR700 automatic plate reader with integral data processor and printer. For all ape A-I calibration curves we used Boehringer Mannheim apelipoprotein calibration serum, reconstituted and stored at -70 #{176}C in aliquots, and used when required.
Chemical treatments of fresh human apo A-I serum. We evaluated oethanol, and 10 g/L sodium azide ( To test the possibility of nonspecific binding between solid-phase IgG and oxidized serum substances other than ape A-I proteins, and also with the anti-ape A-I-peroxidase xrnjugate, we proceeded as follows. Ape A-il standard ierum (lot no. 95F-9452; Sigma Chemical Co., St. Louis, IO), which was lyophilized from human plasma containing no ape A-I protein, was assayed by ELISA for ape A-I immunoreactivity before and after oxidation under our 3tandard conditions. We reconstituted this ape A-il stanlard serum and stored it at -16 #{176}C for four months before sasay. We also tested the pessibiity that traces of Na104 in the diluted serum/Na104 solutions could oxidize solidphase antiserum to ape A-I, leading to nonspecific binding Na104 in BSA/PBS, which had the same final concentration of Na104 as diluted serum-oxidation solutions, were assayed by ELISA in the usual way.
We assayed the ape A-I immunoreactivity of five frozen sera, which had been stored at -70 #{176}C for two weeks and contained different ape A-I concentrations, before and after oxidation under our standard conditions. We also prepared five serum solutions with different ape A-I concentrations but similar total protein concentrations, oxidized them under our standard conditions, and assayed them by ELISA. These five serum solutions were obtained by mixing fixed volumes of a normal serum and of a standard ape A-I serum preparation (lot no. A041206D, OSIM 02/03; Behrung ape A-I standard serum) that had been diluted with different amounts of Sigma ape A-il standard serum containing no ape A-I ( Table 2) .
For comparison of oxidation effects on stored nonfrozen and frozen serum ape A-I immunoreactivity, we oxidized, under our standard conditions, five normal serum samples that had been stored at 4#{176}C for 60 days followed by storage at room temperature for 24 h, and five other serum samples that had been stored at -70 #{176}C for two weeks. All the chemically treated and untreated corresponding sara were then diluted 100-fold in BSA/PBS to give a final serum dilution of 104-fold and assayed for ape A-I immunoreactivity in the same ELLSA plate. Sera for these experiments were obtained from healthy normolipidemic adult laboratory staff members after an overnight fast. Reagents were of analytical quality.
We used the conventional statistical calculation of coefficient of variation (CV). Twenty replicates placed in six different plates were tested for this purpose. We routinely assayed samples in duplicate, and checked the CV by precision proffle (19). Least squares linear regression was used for the correlation study.
Results
General chemical treatments of fresh serum. Serum that was treated with Na104 had a 52.5-fold increase in ape A-I immunoreactivity (Table 1) . Ape A-I values of serum treated with HC1 increased 5.08-fold. Serum that had been exposed to either EDTA or NaBH4 showed little change in ape A-I concentration, whereas treatment with NaOH or urea decreased ape A-I values. Delipidation by diethyl ether/ethanol decreased measurable serum ape A-I values to 19% of the values for untreated serum. Ape A-I concentrations were also decreased by detergent treatment; Tween 20, Triton X-100, Teric, and SDS respectively lowered ape A-I values to 45%, 54%, 35%, and 10% of those for untreated serum. The serum without treatment had a mean ape A-I concentration of 804 mg/L.
Nonspecific reactions. We performed the following control peaked at 100 miii, followed by an extended plateau to at least 240 mm. Oxidation of sera containing different apo A-I concentra tions but similar total protein concentrations.
The extent ol the increase in measured ape A-I values in sera oxidized b Na104 varied from subject to subject and was not proper. tional to the original serum ape A-I values (Table 3) . Thit was true for both fresh and stored sera.
In contrast, serum solutions with different ape A-I conS centrations ranging from 249 to 709 mg/L, prepared froni the same ape A-I source and containing similar tots] protein concentrations, showed a consistent and proper. tional increase in their iminunoreactivities after Na104 oxidation (Figure 2) .
Oxidation of apoA -I in previously stored sera. Sara stored at 4#{176}C for 60 days before assay had increased ape A-] immunoreactivity (Table 3) , but Na104 oxidation still in. creased their measurable ape A-I immunoreactivities fur. ther. Stored nonfrozen sara had smaller increases of mea' surable ape A-I after Na104 oxidation than did oxidized frozen serum (P = 0.0004) ( Table 3) .
Discussion
This study confirms that ape A-I immunoreactivity as measured by ELISA assay using Boebringer Mannhein pelyclonal anti-ape A-I antiserum increases during storage at 4#{176}C, and it establishes that serum oxidation in vitro b Na104 also increases immunoreactivity, whereas delipida. tion and denaturation do not. The study further shows thai the increased reactivity after periodate oxidation is not attributable to nonspecific binding between either oxidized non-ape A-I serum substances or solid-phase IgG and thE conjugate molecules, but is related to the concentration oi serum ape A-I proteins.
Of the several other chemical treatments of fresh serum the only one that enhanced ape A-I immunoreactivity was exposure to 1 mol/L hydrochloric acid, a treatment thai might expose hidden antigemc sites by hydrolysis of amide, peptide, or glycosidic bonds. The reported changes of apc A-I immunoreactivity after delipidation vary from report ti experiments to test whether the increase in ape A-I immunoreactivity of Na104-oxidized serum was caused by an increase in the formation of the specific oxidized serum ape A-I-antibody complex or by nonspecific interactions that linked the conjugated horseradish peroxidase to the solid phase. Firstly, we oxidized Sigma ape A-il standard serum with Na104 and then assayed for ape A-I by ELISA. There was no cross-reaction between ape A-il serum and anti-ape A-I antiserum, either before or after oxidation of ape A-il serum, compared with the blank wells. This result showed that Na104 oxidation of some serum components other than ape A-I did not increase reactivity in the ape A-I ELISA assay. Secondly, microwells pre-coated with anti-ape A-I antiserum were exposed to diluted Na104 in BSAJPBS, which had the same concentration of Na104 as that in serum samples, which had first been oxidized with 200 mmol/L Na.104, and then diluted for ape A-I assay. We observed no reactivity in these wells by comparison with blank wells. This finding ruled out the possibility that the increased immunoreactivity induced by Na104 was the result of a reaction of solid phase with the oxidant and anti-ape A-I conjugate.
The Na104 concentration dependence and the time course of the oxidation of apo A-I in serum. We oxidized serum with various concentrations of Na104 from 0.1 to 200 mmoIJL at room temperature for 20 mm. The value for measurable ape A-I in oxidized serum increased with increasing NaIO4 concentration. The response was essentially linear from 1 up to 200 mmol/L.
In a preliminary experiment, the increase in the immunoreactivity caused by oxidation of serum with 100 munol/L Na104 at 25#{176}C was not complete up to 50 mm. In subsequent experiments, we found that the increased imununoreactivity of ape A-I with oxidation was complete before or at 1 h in the presence of 200, 100, and 50 mmol of Na104 per liter at 37#{176}C, and in the presence of 200 and 100 mmol/L at 25#{176}C. The immunoreactivity peaked between 2 and 3 h at 50 mmol/L Na104, at 25 #{176}C. Subsequently, there was a marked decline of immunoreactivity under all these oxidation conditions. The decline in the immunoreactivity was more rapid at higher concentrations of Na104, and was also faster at 37 #{176}C than at 25#{176}C. A more detailed study of the time course of immunoreactivity changes between 10 and 240 minis shown in Figure 1 . Oxidation in 100 mmoIJL Na104 at 25#{176}C resulted in the immunoreactivity peaking at 30 mm, followed by a plateau (i.e., lack of change) for 30 miii and then a decline. Oxidation in 10 mmoIJL Na104 at 25 #{176}C caused a slower increase in immunoreactivity, which against purified ape A-I as the immunogen, were more reactive with stored non-frozen serum, which had more oxidized ape A-I forms. By contrast, monoclonal anti-ape A-I antibodies against freshly prepared HDL reacted more strongly or equally with fresh serum ape A-I than with stored nonfrozen serum (14).
In the present experiments, Boehringer Mannheim antiserum to ape A-I reacted avidly with oxidized ape A-I. We could postulate, therefore, that oxidized ape A-I had either antigenic sites different from those of reduced ape A-I, or that in the oxidized form the antigenic sites were more accessible.
In addition, immunogens
used for the Boehringer Mannheim antiserum preparation probably had a higher proportion of oxidized ape A-I, because it had been 0.3 0.4 0.5 0.6 0.7 0.8 purifiedbeforeinjection.Previousstudies (14) haveshown that when antioxidants were added to serum, the increased ape A-I immunoreactivity could be attenuated. It was of particular interest that the immunoreactivity of ape A-I that was exposed to Na104 initially increased rapidly to reach a plateau, then declined (Figure 1) . Apparently, oxidation of a very susceptible site on the ape A-I molecule is responsible for the rapid increase. From the foregoing, this site is likely to be methionine residue(s) (25) . Further oxidation of ape A-I at this or at other sites could lead to its denaturation, accounting for the slow decline in immunoreactivity.
Our results suggest that the difficulty in the international standardization of ape A-I assays could be due in part to the presence of reduced and oxidized ape A-I forms in vitro and changes in their concentrations with storage. This is also related to the choice and storage of the calibration ape A-I serum. However, whether the oxidized ape A-I form exists in vivo and, if so, whether it has a different biological role than does the reduced ape A-I form, is still unclear. In particular, the presence of oxidized ape A-I could have relevance to the protective role of ape A-I against atherogenesis.
From the foregoing it is clear that accurate estimation of the total concentration of ape A-I in serum by immunoassay is rendered difficult by the presence of the interconverting oxidized and non-oxidized forms. One potential solution to this dilemma would be to use a monoclonal antibody specific for an epitope of ape A-I that is unaffected by the oxidation state of the apoprotein. We have no explanation for these differences.
CLINICALCHEMISTRY
The present results suggest that increased ape A-I immunoreactivity during storage could result from slow oxidation either by air or by lipid peroxide and that this occurs at different rates in different subjects, as was seen in the in vitro oxidation study. It is noteworthy that further increases in ape A-I immunoreactivity resulted from oxidation with Na104, even after storage at 4#{176}C for 60 days. However, stored nonfrozen serum was oxidized with Na104 to a lesser extent than was frozen serum when the same oxidation conditions were used. It also should be emphasized that the sensitivity of serum to either natural oxidation or in vitro Na104 oxidation differed from subject to subject, suggesting the involvement of additional factors in the oxidation reaction.
We have no data to clarify these differences, but the explanation may lie with the two forms of ape A-I proteins shown to be present in normal human plasma in vitro (23). Anantharamaiah et al. (23) identified oxidized and reduced forms of ape A-I, which could be separated by high performance liquid chromatography, and also showed that three methionine residues in the ape A-I protein were the potential oxidation sites. They (23) were able to convert the reduced isomers to the oxidized forms with hydrogen peroxide. They also found that different batches of purified ape A-I had different proportions of these two forms. Hughes et al. (24) further showed that, in serum stored at 4#{176}C for longer than one month, the oxidized ape A-I form increased, but that this could be minimized by storing at -20 #{176}C. It follows that different ape A-I preparations used as immunogens to raise antiserum could contain different proportions of the oxidized and non-oxidized forms of ape A-I. These preparations might produce antisera containing antibodies towards either the oxidized form of ape A-I or the reduced form or both. In support of this Marcel et al. (14) found that monoclonal antibodies to ape A-I, prepared
In conclusion, the present studies suggest strongly that enhanced immunoreactivity of ape A-I in serum during storage is mainly due to oxidation of the ape A-I. In addition, the magnitude of this effect seems to depend upon the antiserum and methodology used. The nature of the ape A-I immunogen used to raise antiserum could have an impertant influence on the measured increase in immunoreactivity associated with sample storage.
